# Aurobindo Pharma Limited - Inspection Records

Source: https://www.keypedia.com/companies/aurobindo-pharma-limited/9bedb5d4-0483-4173-bc76-1c5737a28fc1

> Inspection records and compliance data for Aurobindo Pharma Limited in Bachupally, None. Access full analysis and detailed observations.

---

## Details

- Name: Aurobindo Pharma Limited
- FEI Number: 3004446312
- City: Bachupally
- State: None
- Country Name: India
- Address Line 1: 314 Medchal - - Malkajgiri District, Unit 12; Survey No
- Zip Code: None
- Business Operations: API/FDF ANALYTICAL TESTING, FDF MANUFACTURE

## Related Documents

- [483 - Aurobindo Pharma Limited - 2025-09-05](https://www.keypedia.com/records/483/aurobindo-pharma-limited/8b69c4b7-aaed-4b33-b6bf-a174746cb97c) — source: FDA, date: September 5, 2025
- [483 - Aurobindo Pharma Limited - 2025-09-05](https://www.keypedia.com/records/483/aurobindo-pharma-limited/53eddf59-189f-410e-94a4-1b28f676d6d6) — source: FDA, date: September 5, 2025
- [483 - Aurobindo Pharma Limited - 2025-09-05](https://www.keypedia.com/records/483/aurobindo-pharma-limited/31ac5498-c32b-4f35-b9ad-a996d6e6c456) — source: FDA, date: September 5, 2025
- [FDA Inspection 1286862 - Aurobindo Pharma Limited - 2025-09-05](https://www.keypedia.com/records/fda_inspections/aurobindo-pharma-limited/e27c7a63-48f1-4316-8130-b5019c93f3db) — source: FDA, date: September 5, 2025
- [FDA Inspection 1286862 - Aurobindo Pharma Limited - 2025-09-05](https://www.keypedia.com/records/fda_inspections/aurobindo-pharma-limited/bad39678-8eb7-42c7-b820-7b3bab50ca4f) — classification: Official Action Indicated (OAI), source: FDA, date: September 5, 2025
- [FDA Inspection 1241780 - Aurobindo Pharma Limited - 2023-03-09](https://www.keypedia.com/records/fda_inspections/aurobindo-pharma-limited/11833527-0353-45ec-967e-1b9b8ade4fdf) — classification: Voluntary Action Indicated (VAI), source: FDA, date: March 9, 2023
- [483 - Aurobindo Pharma Limited - 2020-02-21](https://www.keypedia.com/records/483/aurobindo-pharma-limited/892c968e-c743-4108-bf0a-b6616316dc36) — source: FDA, date: February 21, 2020
- [FDA Inspection 1118385 - Aurobindo Pharma Limited - 2020-02-21](https://www.keypedia.com/records/fda_inspections/aurobindo-pharma-limited/6c77bf62-e7b5-45b7-ad26-a5543e122130) — classification: Voluntary Action Indicated (VAI), source: FDA, date: February 21, 2020
- [FDA Inspection 1118385 - Aurobindo Pharma Limited - 2020-02-21](https://www.keypedia.com/records/fda_inspections/aurobindo-pharma-limited/c9b52e8f-bf77-492c-8a49-f01a2f3d34e0) — classification: Voluntary Action Indicated (VAI), source: FDA, date: February 21, 2020
- [483 - Aurobindo Pharma Limited - 2020-02-17](https://www.keypedia.com/records/483/aurobindo-pharma-limited/733cada2-a1ca-47e0-b637-93e8c8b28dd8) — source: FDA, date: February 17, 2020
- [FDA Inspection 1046218 - Aurobindo Pharma Limited - 2018-03-16](https://www.keypedia.com/records/fda_inspections/aurobindo-pharma-limited/5d8760ef-fede-4b1f-82af-36c3aecf92c5) — classification: Voluntary Action Indicated (VAI), source: FDA, date: March 16, 2018
- [FDA Inspection 1046218 - Aurobindo Pharma Limited - 2018-03-16](https://www.keypedia.com/records/fda_inspections/aurobindo-pharma-limited/d4cc3587-20be-4443-8712-6e49c304278b) — classification: Voluntary Action Indicated (VAI), source: FDA, date: March 16, 2018
- [FDA Inspection 847151 - Aurobindo Pharma Limited - 2013-08-16](https://www.keypedia.com/records/fda_inspections/aurobindo-pharma-limited/43183e2b-7f58-44fb-9134-fdbca5710164) — classification: No Action Indicated (NAI), source: FDA, date: August 16, 2013
- [FDA Inspection 847151 - Aurobindo Pharma Limited - 2013-08-16](https://www.keypedia.com/records/fda_inspections/aurobindo-pharma-limited/76f16784-f959-4467-baf8-dd96ecc6fb14) — classification: No Action Indicated (NAI), source: FDA, date: August 16, 2013
- [FDA Inspection 793023 - Aurobindo Pharma Limited - 2012-06-26](https://www.keypedia.com/records/fda_inspections/aurobindo-pharma-limited/de49d5a6-4b83-440a-9703-ee48be6d0a2c) — classification: Voluntary Action Indicated (VAI), source: FDA, date: June 26, 2012

## Related Companies

- [Alcami Carolinas Corporation](https://www.keypedia.com/companies/alcami-carolinas-corporation/87394b03-3fcf-4acb-836a-8c46cc6881c2)
- [Vetter Pharma Fertigung GmbH & Co. KG](https://www.keypedia.com/companies/vetter-pharma-fertigung-gmbh-co-kg/6b51041e-37a7-4672-a7e2-c3c871d6231b)
- [Shiseido America Inc.](https://www.keypedia.com/companies/shiseido-america-inc/612a919a-3309-4649-b8bf-d8cd6af8ed5a)
- [Vetter Pharma Fertigung GmbH & Co. KG](https://www.keypedia.com/companies/vetter-pharma-fertigung-gmbh-co-kg/9c78f7c1-8016-4128-9dc3-ce5b4e0e0d44)
- [WuXi Advanced Therapies](https://www.keypedia.com/companies/wuxi-advanced-therapies/2d12016c-2b9d-4b5e-91a8-4f8af5bee2e1)
- [MSN Laboratories Private Limited (Formulations Division, Unit-II)](https://www.keypedia.com/companies/msn-laboratories-private-limited-formulations-division-unit-ii/44914049-4b84-4bac-abac-9af09a223eb8)
- [Pacira Pharmaceuticals, Inc.](https://www.keypedia.com/companies/pacira-pharmaceuticals-inc/0062419b-850d-4eea-ad5d-918907be2e52)
- [Quotient Sciences - Philadelphia, LLC](https://www.keypedia.com/companies/quotient-sciences-philadelphia-llc/21968347-fe31-4ffc-801c-5253fa909968)
- [Seqirus Pty Ltd](https://www.keypedia.com/companies/seqirus-pty-ltd/673f8bd1-d8ea-4125-a3cf-a83827b17359)
- [Agnitio Inc](https://www.keypedia.com/companies/agnitio-inc/6bcd09b9-e002-45bf-805c-0e4474b1bdfb)

## Related Officers

- [Xiaohong Lu](https://www.keypedia.com/people/xiaohong-lu/c090ea51-c732-4d96-8063-30a8f2eb21ba)
- [Advisor](https://www.keypedia.com/people/frederick-razzaghi/7346f6ec-1d9a-4ad3-abde-0497dcd9c8b5)
- [Joseph A. Piechocki](https://www.keypedia.com/people/joseph-a-piechocki/1977a57b-4976-4b01-b8da-66a84b26e803)
- [Claudia Perez-Kamarski](https://www.keypedia.com/people/claudia-perez-kamarski/b7020978-e2e4-43b0-b2c6-eb861a1a85d0)